Peter Melnyk - Alpha Tau Chief Officer

Alpha Tau Management Efficiency

The company has return on total asset (ROA) of (0.2192) % which means that it has lost $0.2192 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3317) %, meaning that it created substantial loss on money invested by shareholders. Alpha Tau's management efficiency ratios could be used to measure how well Alpha Tau manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 0.37 in 2024, whereas Return On Tangible Assets are likely to drop (0.29) in 2024. At this time, Alpha Tau's Net Tangible Assets are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 669.9 K in 2024, whereas Non Current Assets Total are likely to drop slightly above 11.5 M in 2024.

Similar Executives

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of solid cancer In Israel and the United States. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel. Alpha Tau is traded on NASDAQ Exchange in the United States. Alpha Tau Medical (DRTS) is traded on NASDAQ Exchange in USA. It is located in Kiryat Hamada Street 5, Jerusalem, Israel, 9777605 and employs 121 people. Alpha Tau is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Alpha Tau Medical Leadership Team

Alpha Stock Performance Indicators

Additional Tools for Alpha Stock Analysis